Arcellx, Inc.
General ticker "ACLX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.9B (TTM average)
Arcellx, Inc. follows the US Stock Market performance with the rate: 50.0%.
Estimated limits based on current volatility of 3.9%: low 66.60$, high 72.63$
Factors to consider:
- Total employees count: 163 (+25.4%) as of 2024
- Top business risk factors: Limited operating history, Third-party risks, Insufficient funding, Regulatory and compliance, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [42.89$, 87.75$]
- 2025-12-31 to 2026-12-31 estimated range: [32.91$, 69.89$]
Financial Metrics affecting the ACLX estimates:
- Negative: with PPE of -38.5 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.02 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -3.95 <= -0.75
- Positive: -4.48 < Investing cash flow per share per price, % of -4.43
- Positive: Shareholder equity ratio, % of 63.94 > 63.39
Short-term ACLX quotes
Long-term ACLX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $110.32MM | $107.94MM |
| Operating Expenses | $191.26MM | $200.20MM | $245.51MM |
| Operating Income | $-191.26MM | $-89.88MM | $-137.57MM |
| Non-Operating Income | $2.58MM | $19.85MM | $32.29MM |
| R&D Expense | $149.56MM | $133.85MM | $157.09MM |
| Income(Loss) | $-188.68MM | $-70.03MM | $-105.28MM |
| Taxes | $0.00MM | $0.66MM | $2.07MM |
| Profit(Loss)* | $-188.68MM | $-70.69MM | $-107.35MM |
| Stockholders Equity | $204.95MM | $485.38MM | $454.79MM |
| Assets | $313.82MM | $825.13MM | $711.33MM |
| Operating Cash Flow | $-99.30MM | $207.57MM | $-83.47MM |
| Capital expenditure | $2.28MM | $21.43MM | $13.43MM |
| Investing Cash Flow | $-117.67MM | $-154.51MM | $-183.04MM |
| Financing Cash Flow | $252.62MM | $279.16MM | $-24.09MM |
| Earnings Per Share** | $-4.28 | $-1.47 | $-2.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.